SCHEMBL12018317

SCHEMBL12018317

CC(C)NC(=O)C(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 8/20 0.52
CES1 P23141 7/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
MAPT P10636 2/20 0.52
XBP1 P17861 1/20 0.52
ATM Q13315 1/20 0.52
ALDH1A1 P00352 4/20 0.49
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
CDK5 Q00535 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
GAA P10253 1/20 0.44
ALOX12 P18054 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9388831 0.82 SMN1; SMN2 (0.47) CES2CES1SMN1; SMN2LMNANPSR1
SCHEMBL14397456 0.82 LMNA (0.54) CES2CES1SMN1; SMN2LMNANPSR1
SCHEMBL6749595 0.80 SMN1; SMN2 (0.48) SMN1; SMN2LMNANPSR1MAPTXBP1
SCHEMBL26347289 0.80 ALDH1A1 (0.49) SMN1; SMN2LMNANPSR1MAPTXBP1
SCHEMBL8802723 0.80 CES2 (0.56) CES2CES1SMN1; SMN2LMNAMAPT
SCHEMBL24998749 0.78 MLYCD (0.58) SMN1; SMN2LMNANPSR1ALDH1A1CYP1A2
SCHEMBL155518 0.78 MLYCD (0.58) SMN1; SMN2LMNANPSR1ALDH1A1CYP1A2
SCHEMBL29772431 0.78 MLYCD (0.58) SMN1; SMN2LMNANPSR1ALDH1A1CYP1A2
SCHEMBL13875459 0.78 MEN1 (0.52) CES2CES1SMN1; SMN2LMNANPSR1
SCHEMBL27432290 0.78 SMN1; SMN2 (0.43) CES2CES1SMN1; SMN2LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951058-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2018-04-24 US disclosed
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 US disclosed
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 US disclosed
EP-1836002-B1 PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT COATINGS BASF SE (DE) 2012-08-29 EP disclosed